摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-formylaminothiophene-3-carboxamide | 43028-71-3

中文名称
——
中文别名
——
英文名称
2-formylaminothiophene-3-carboxamide
英文别名
2-formylamino-thiophene-3-carboxylic acid amide;2-Formamidothiophene-3-carboxamide
2-formylaminothiophene-3-carboxamide化学式
CAS
43028-71-3
化学式
C6H6N2O2S
mdl
——
分子量
170.192
InChiKey
KXAVFPNUFRCVTC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    193 °C (decomp)
  • 沸点:
    450.0±30.0 °C(Predicted)
  • 密度:
    1.487±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    100
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S
    申请人:Lyons John Francis
    公开号:US20100021420A1
    公开(公告)日:2010-01-28
    A combination comprising (a) a compound of formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is R 1 -A-NR 4 — or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO 2 , C═O, NR 9 (C═O) or 0(C═O) wherein R 9 is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1 to 3 carbon atoms; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or an optionally substituted C 1-8 hydrocarbyl group wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy; or a C 1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C 1-4 alkoxy; R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C 1-4 alkoxy; and (b) a compound of formula (I′″) or salts, tautomers, solvates and N-oxides thereof: wherein R 1 is 2,6-dichlorophenyl; R 2a and R 2b are both hydrogen; and R 3 is a group: formula (A) where R 4 is C 1-4 alkyl.
    一个组合物,包括(a)式(0)的化合物:或其盐或互变异构体或N-氧化物或溶剂合物;其中X为R1-A-NR4-或5-或6-成员的碳环或杂环环;A为键,SO2,C═O,NR9(C═O)或0(C═O),其中R9为氢或C1-4烃基,可选择地被羟基或C1-4烷氧基取代;Y为键或1至3个碳原子的烷基链;R1为氢;具有3至12个环成员的碳环或杂环基;或可选择地被卤代、羟基或C1-4烷氧基取代的C1-8烃基,其中烃基的1或2个碳原子可选择地被从O、S、NH、SO、SO2中选择的原子或基团取代;R2为氢;卤素;C1-4烷氧基;或可选择地被卤代、羟基或C1-4烷氧基取代的C1-4烃基;R3选自氢和具有3至12个环成员的碳环或杂环基;和R4为氢或可选择地被卤代、羟基或C1-4烷氧基取代的C1-4烃基;和(b)式(I′″)的化合物或其盐、互变异构体、溶剂合物和N-氧化物:其中R1为2,6-二氯苯基;R2a和R2b均为氢;和R3为一个基团:式(A),其中R4为C1-4烷基。
  • [EN] 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS<br/>[FR] COMPOSES 1H-PYRAZOLE 3,4-DISUBSTITUES ET LEUR UTILISATION EN TANT QUE KINASES DEPENDANT DES CYCLINES (CDK) ET MODULATEURS DE LA GLYCOGENE SYNTHASE KINASE-3 (GSK-3)
    申请人:ASTEX TECHNOLOGY LTD
    公开号:WO2005012256A1
    公开(公告)日:2005-02-10
    The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. Formula (0). In formula (0): X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, S02, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from 0, S, NH, SO, S02; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).
    该发明提供了以下式(0)的化合物或其盐或互变异构体或N-氧化物或其溶剂合物,用于预防或治疗由细胞周期依赖性激酶和糖原合成酶-3介导的癌症等疾病状态和病症。在式(0)中:X是一个基团R1-A-NR4-或一个5-或6-成员的碳环或杂环;A是一个键,S02,C=O,NRg(C=O)或O(C=O),其中Rg是氢或C1-4烃基,可以选择性地被羟基或C1-4烷氧基取代;Y是一个键或一个由1、2或3个碳原子组成的烷基链;R1是氢;一个具有3到12个环成员的碳环或杂环基团;或一个C1-8烃基,可以选择性地被卤素(如氟)、羟基、C1-4烷氧基、氨基、单或双C1-4烃基氨基以及具有3到12个环成员的碳环或杂环基团取代,其中烃基的1或2个碳原子可以选择性地被从0、S、NH、SO、S02中选择的原子或基团所取代;R2是氢;卤素;C1-4烷氧基(如甲氧基);或一个C1-4烃基,可以选择性地被卤素(如氟)、羟基或C1-4烷氧基(如甲氧基)取代;R3从氢和具有3到12个环成员的碳环或杂环基团中选择;R4是氢或一个C1-4烃基,可以选择性地被卤素(如氟)、羟基或C1-4烷氧基(如甲氧基)取代。
  • PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA
    申请人:Curry Jayne Elizabeth
    公开号:US20100055094A1
    公开(公告)日:2010-03-04
    The invention provides combinations of an ancillary compound and a compound which is a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. Also provided are crystalline forms of the salts, methods for making the salts and their uses in treating cancers. The invention further provides combinations of an ancillary compound and a compound of the formula (I) as defined in PCT/GB2004/002824 (WO 2005/002552) or a compound of the formula (I′) or a salt, solvate, tautomer or N-oxide thereof, wherein R 1 , E, A and M are as defined in the claims.
    该发明提供了一种辅助化合物和一种盐化合物的组合物,所述盐化合物为1-环丙基-3-[3-(5-吗啉-4-基甲基-1H-苯并咪唑-2-基)-1H-吡唑-4-基]-脲的盐,所述盐选自乳酸盐和柠檬酸盐及其混合物。还提供了所述盐的晶型形式,制备所述盐的方法以及它们在治疗癌症中的用途。该发明进一步提供了一种辅助化合物和根据PCT/GB2004/002824(WO 2005/002552)中定义的式(I)或式(I')的化合物的组合物,或者其盐、溶剂化合物、互变异构体或N-氧化物,其中R1、E、A和M如权利要求中所定义。
  • [EN] 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS<br/>[FR] COMPOSES 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE KINASES CYCLINE-DEPENDANTES (CDK)
    申请人:ASTEX TECHNOLOGY LTD
    公开号:WO2004014864A1
    公开(公告)日:2004-02-19
    The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2-R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R1 is hydrogen or a group selected from SO2Rb,SO2NR7R8,CONR7R8,NR7R9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R3, to R9 are defined in the description but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.
    本发明提供了一种式(I)化合物,用于预防或治疗由细胞周期蛋白依赖性激酶介导的疾病状态或条件:其中A是R2基团或CH2-R2,其中R2是具有3至12个环成员的碳环或杂环基团;B是键或具有最多3个原子(选自C、N、S和O)的链长的不饱和链连接基团;R1是氢或选自SO2Rb、SO2NR7R8、CONR7R8、NR7R9以及具有3至7个环成员的碳环和杂环基团;R3至R9在说明书中定义,但不包括化合物N-[(吗啉-4-基)苯基-1H-吲唑-3-甲酰胺]和N-[4-(乙酰氨基磺酰基)苯基-1H-吲唑-3-甲酰胺]。
  • Microwave-assisted synthesis of 2-aminothiophene-3-carboxylic acid derivatives, 3H-thieno[2,3-d]pyrimidin-4-one and 4-chlorothieno[2,3-d]pyrimidine
    作者:Stéphanie Hesse、Enrico Perspicace、Gilbert Kirsch
    DOI:10.1016/j.tetlet.2007.05.136
    日期:2007.7
    A two-minute microwave irradiation allowed the synthesis of several 2-aminothiophene-3-carboxylic acid derivatives. Their efficient transformation to thieno[2,3-d]pyrimidin-4-one and the corresponding 4-chloro derivative is also reported under microwave irradiation.
    两分钟的微波辐射允许合成几种2-氨基噻吩-3-羧酸衍生物。还报道了它们在微波辐射下有效转化为噻吩并[2,3 - d ]嘧啶-4-酮和相应的4-氯衍生物。
查看更多

同类化合物

阿罗洛尔 阿替卡因 阿克兰酯 锡烷,(5-己基-2-噻吩基)三甲基- 邻氨基噻吩(2盐酸) 辛基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 辛基4,6-二溴噻吩并[3,4-b]噻吩-2-羧酸酯 辛基2-甲基异巴豆酸酯 血管紧张素IIAT2受体激动剂 葡聚糖凝胶LH-20 苯螨噻 苯并[c]噻吩-1-羧酸,5-溴-4,5,6,7-四氢-3-(甲硫基)-4-羰基-,乙基酯 苯并[b]噻吩-2-胺 苯并[b]噻吩-2-胺 苯基-[5-(4,4,5,5-四甲基-[1,3,2]二氧杂硼烷-2-基)-噻吩-2-基亚甲基]-胺 苯基-(5-氯噻吩-2-基)甲醇 苯乙酸,-α--[(1-羰基-2-丙烯-1-基)氨基]- 苯乙酰胺,3,5-二氨基-a-羟基-2,4,6-三碘- 苯乙脒,2,6-二氯-a-羟基- 腈氨噻唑 聚(3-丁基噻吩-2,5-二基),REGIOREGULAR 硝呋肼 硅烷,(3-己基-2,5-噻吩二基)二[三甲基- 硅噻菌胺 盐酸阿罗洛尔 盐酸阿罗洛尔 盐酸多佐胺 甲酮,[5-(1-环己烯-1-基)-4-(2-噻嗯基)-1H-吡咯-3-基]-2-噻嗯基- 甲基5-甲酰基-4-甲基-2-噻吩羧酸酯 甲基5-乙氧基-3-羟基-2-噻吩羧酸酯 甲基5-乙基-3-肼基-2-噻吩羧酸酯 甲基5-(氯甲酰基)-2-噻吩羧酸酯 甲基5-(氯乙酰基)-2-噻吩羧酸酯 甲基5-(氨基甲基)噻吩-2-羧酸酯 甲基5-(4-甲氧基苯基)-2-噻吩羧酸酯 甲基5-(4-甲基苯基)-2-噻吩羧酸酯 甲基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 甲基4-硝基-2-噻吩羧酸酯 甲基4-氰基-5-(4,6-二氨基吡啶-2-基)偶氮-3-甲基噻吩-2-羧酸酯 甲基4-氨基-5-(甲硫基)-2-噻吩羧酸酯 甲基4-{[(2E)-2-(4-氰基苯亚甲基)肼基]磺酰}噻吩-3-羧酸酯 甲基4-(氯甲酰基)-3-噻吩羧酸酯 甲基4-(氨基磺酰基氨基)-3-噻吩羧酸酯 甲基3-甲酰氨基-4-甲基-2-噻吩羧酸酯 甲基3-氨基-5-异丙基-2-噻吩羧酸酯 甲基3-氨基-5-(4-溴苯基)-2-噻吩羧酸酯 甲基3-氨基-4-苯基-5-(三氟甲基)-2-噻吩羧酸酯 甲基3-氨基-4-氰基-5-甲基-2-噻吩羧酸酯 甲基3-氨基-4-丙基-2-噻吩羧酸酯 甲基3-[[(4-甲氧基苯基)亚甲基氨基]氨基磺酰基]噻吩-2-羧酸酯